arrow_back Back to App

Improved Foreign Drug Inspections: Safer Medicines for Citizens

This act aims to enhance the safety of medicines available in the United States, especially those manufactured abroad. It introduces new rules for inspecting foreign drug factories to ensure that the medicines you purchase are safe and effective. This gives citizens greater confidence in the quality of the medications they take.
Key points
Strengthening inspections of foreign drug factories, including considering the history of quality issues in a given country.
Allowing the use of existing data and previous inspections for drug approvals, potentially speeding up availability.
Increased cooperation with foreign governments on mutual recognition of inspections to streamline processes.
A report to Congress evaluating the effectiveness of new inspection methods and opportunities for further development.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7006
Sponsor: Rep. Griffith, H. Morgan [R-VA-9]
Process start date: 2022-03-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

INSPECTIONS Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7006.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-09.

What are the main provisions?

Key points include:

  • Strengthening inspections of foreign drug factories, including considering the history of quality issues in a given country.
  • Allowing the use of existing data and previous inspections for drug approvals, potentially speeding up availability.
  • Increased cooperation with foreign governments on mutual recognition of inspections to streamline processes.
  • A report to Congress evaluating the effectiveness of new inspection methods and opportunities for further development.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Griffith, H. Morgan [R-VA-9].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health